Global Infusion Devices Market Set To Grow To $12.3bn By 2022

Tuesday 20 February 2018, Amsterdam

The key player has launched a new pharma report Global Infusion Devices Market Forecast to 2027: Infusion Pumps, Insulin Pumps, Enteral Feeding Pumps, other Infusion Pumps.

Infusion pumps have been a reliable source of drug delivery for nearly a century. These infusion devices can be used to treat a wide range of therapeutic areas including analgesia, chemotherapy, diabetes and clinical nutrition, thus making them an invaluable tool in modern medicine. With the advent of modern medical devices the infusion pump market has become one of the fastest growing drug delivery segments within the market. This rapid growth is projected due to the nature of the illnesses which infusion pumps are used to treat.

The lead analyst of the report commented “The key player has identified several issues and trends impacting the future of the infusion pumps market. Ageing populations, increasing incidence of diseases - particularly diabetes, and increasing healthcare coverage in developing countries will continue to fuel market growth in the future.

Key issues and trends explored in this report include: increasing life expectancy worldwide, growing incidence of disease, worldwide spending on healthcare, infusion pump health risks and recalls, new regulations in leading national markets, smart pump technology and a shift from hospital to home health care.”

Leading companies featured in the report include ALCOR Scientific, Altea Therapeutics, Animas Corporation, B.Braun, Baxter, CareFusion, Cellnovo, Covidien, D. Medical Industries, Danone Nutricia, Debiotech, Disetronic (Roche), Fresenius Kabi, Hospira, Insulet CorporationJohnson & Johnson, Medline, MedSolve Technologies, Medtronic, Q Core Medical, Roche, Smiths Medical SOOIL, Tandem Diabetes Care, Valeritas, Zevex.